Treveri

Artio Medical Hires Key Sales and Marketing Leaders to Prepare for Commercial Launch of First Product in U.S.

Retrieved on: 
Tuesday, June 15, 2021
Artio, Treveri, Medical device

Weinrich and Parker have joined Artio to prepare the company for the planned U.S. market release of it first anticipated commercial product, the Solus Gold Embolization Device.

Key Points: 
  • Weinrich and Parker have joined Artio to prepare the company for the planned U.S. market release of it first anticipated commercial product, the Solus Gold Embolization Device.
  • "We are excited to welcome Jeff and Chris to the Artio team", said Dr. F. Nicholas Franano, President and CEO of Artio Medical.
  • Weinrich comes to Artio with over 30 years of senior sales executive experience in the medical device industry.
  • Artio Medical is a medical device company committed to developing innovative products for the treatment of peripheral vascular, neurovascular, and structural heart diseases.

Artio Medical Appoints Nathaniel Hagedorn to Board of Directors

Retrieved on: 
Tuesday, April 28, 2020
Artio, Treveri

FAIRWAY, Kan., April 28, 2020 /PRNewswire/ -- Artio Medical, Inc. (Artio), a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announced the appointment of entrepreneur and businessman Nathaniel Hagedorn to its Board of Directors.

Key Points: 
  • FAIRWAY, Kan., April 28, 2020 /PRNewswire/ -- Artio Medical, Inc. (Artio), a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announced the appointment of entrepreneur and businessman Nathaniel Hagedorn to its Board of Directors.
  • "We are pleased to welcome Nathaniel to Artio's Board," commented F. Nicholas Franano, President and CEO of Artio.
  • As Artio raises additional capital and launches commercial operations, we look to Nathaniel's leadership to help guide us forward."
  • Artio Medical is a medical device company committed to developing innovative endovascular products for the treatment of peripheral vascular, neurovascular, and structural heart diseases.